Ainos signs VELDONA license deal with BioPhoenix worth up to $10 million
Bitget2026/09/24 12:00- Ainos signed a VELDONA license deal with BioPhoenix, setting a conditional collaboration framework valued at up to USD 10 million.
- BioPhoenix secured exclusive worldwide rights for Sjögren's disease and thrombocytopenia, covering development, manufacturing, and commercialization.
- BioPhoenix will fund and run assigned clinical and regulatory work, shifting late-stage development costs away from Ainos.
- Framework includes an upfront license fee, potential payments for up to 15 additional indications, and a one-time fee on BioPhoenix’s first sublicense.
- Ainos will receive 25% of applicable net sublicensing revenue, separate from license fees and any product supply revenue.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Circle issues 500 million USDC on the Solana network

Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

